Clinical Trials Browser

Phase 2 × avelumab × Genitourinary × Clear all

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT07460245 2026-03-10

AVESEC

Phase 2 Not yet recruiting

Carcinoma, Transitional Cell

NCT05327530 2026-01-26

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05327686 2026-01-14

SAMURAI

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT07110038 2026-01-12

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Phase 2 Recruiting

Penile Squamous Cell Carcinoma (PSCC)

NCT03391479 2025-12-18

A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

Phase 2 Active not recruiting

Neoplasm Metastasis, Penile Neoplasms

NCT03747419 2025-10-31

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Phase 2 Terminated

14 enrolled 14 charts

Urinary Bladder Neoplasms

NCT04678362 2025-09-22

TALASUR

Phase 2 Recruiting

Carcinoma, Transitional Cell

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06892860 2025-03-25

DISCUS

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03674424 2025-02-26

AURA

Phase 2 Completed

Non-metastatic Muscle Invasive Bladder Cancer

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

4 enrolled 10 charts

Carcinoma, Transitional Cell

NCT04871529 2024-12-30

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Phase 2 Terminated

6 enrolled 12 charts

Urinary Bladder Neoplasms

NCT06424717 2024-09-27

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05574504 2024-08-01

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

Phase 2 Withdrawn

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03770455 2024-07-09

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Phase 2 Terminated

8 enrolled 7 charts

Metastatic Castration-resistant Prostate Cancer

NCT03472560 2024-04-09

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Phase 2 Terminated

61 enrolled 26 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT03390595 2023-10-18

INDUCOMAIN

Phase 2 Completed

Carcinoma, Transitional Cell

NCT05600127 2023-09-08

CHASIT

Phase 2 Recruiting

Carcinoma, Transitional Cell

NCT03774901 2023-04-21

PULSE

Phase 2 Unknown

Penile Neoplasms

NCT05107427 2023-04-18

AVENU

Phase 2 Withdrawn

Carcinoma, Transitional Cell

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03617913 2023-01-06

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Phase 2 Completed

2 enrolled 8 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT04150562 2022-05-17

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

Phase 2 Terminated

2 enrolled 13 charts

Carcinoma, Renal Cell

NCT03324282 2022-05-03

GCISAVE

Phase 2 Terminated

Urinary Bladder Neoplasms

NCT03035630 2022-02-15

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Phase 2 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03179410 2021-03-05

PICK-NEPC

Phase 2 Completed

15 enrolled 12 charts

Prostatic Neoplasms

NCT03950362 2019-05-16

PREVERT

Phase 2 Unknown

Non-Muscle Invasive Bladder Neoplasms

NCT03403777 2019-03-05

Avelumab in Refractory Testicular Germ Cell Cancer.

Phase 2 Completed

Gonadal Disorders, Neoplasms, Neoplasms, Germ Cell and Embryonal, Testicular Diseases, Testicular Neoplasms

NCT03341845 2018-05-21

Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

Phase 2 Unknown

Carcinoma, Renal Cell